Citicholine

Quick links to important sections

Citicholine

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Citicholine

Quick Facts

Property Description
Active Ingredient Citicoline (Cytidine 5'-diphosphocholine)
Pharmacological Class Nootropic and Neuroprotective Agent
Form Oral (tablets/capsules) and Parenteral (solution for injection)
Common Purpose Supports cognitive function and neural structure
Origin Synthetic derivative, identical to the endogenous compound CDP-Choline

What Type of Substance is Citicoline (CDP-Choline)?

Citicoline, formally known by its INN (International Nonproprietary Name) as Citicoline, is a pharmaceutical agent classified as a nootropic and a neuroprotective agent. It is a monocomponent product, containing only the active ingredient, Cytidine 5'-diphosphocholine.

Citicoline is chemically identical to the endogenous compound CDP-Choline, a key intermediate substance naturally synthesized in the body's metabolic pathways. This identity is central to its class as it relates to cellular maintenance. As a medicine, it functions as a precursor compound, offering a direct, medically recognized route for structural and metabolic support within nerve cells. Common brand names globally often featuring this active ingredient include Somazina and Ceraxon.


Forms, Composition, and General Benefit

Citicoline is made available in various dosage forms, including tablets or capsules for oral administration, and as an aqueous solution for injection (parenteral) for intravenous or intramuscular use, offering flexibility for diverse therapeutic needs. The drug's composition involves the active ingredient, Cytidine 5'-diphosphocholine, combined with standard pharmaceutical excipients for solid forms or dissolved in a sterile liquid vehicle for injections.

The general benefit of Citicoline is derived from its high-level function as a membrane stabilizer and cell metabolic supporter. Its function involves facilitating the creation of phospholipids necessary for repairing and maintaining cell structures. Its primary purpose is to promote and maintain healthy cognitive function and provide neuronal protection by supporting the integrity and fluidity of neuronal membranes and assisting in the synthesis of neurotransmitters like acetylcholine.

Regulatory References

  1. NIH Clinical Trials search for Citicoline

What side effects are possible with Citicholine?

Possible Side Effects and Safety Information

The official safety information for Citicoline is structured by regulatory bodies to classify potential adverse reactions based on frequency and affected body system. Most reported side effects are classified as Uncommon (occurring in fewer than 1 in 100 people) or Very Rare (occurring in fewer than 1 in 10,000 people), according to the regulatory frequency framework used by national health agencies.

Adverse reactions documented in the official prescribing information are typically grouped into System-Organ Classes (SOC) and may include:

  • Nervous System Disorders: Such as headache, dizziness, insomnia, and excitement.
  • Gastrointestinal Disorders: Including nausea, vomiting, diarrhea, and stomach pain.
  • Vascular and Cardiac Disorders: Documented effects include transient changes in blood pressure, such as hypotension or hypertension, and changes in heart rhythm.
  • Skin and Immune System Disorders: Reactions may manifest as rash or redness.

Very Rare events documented in regulatory sources include severe hypersensitivity reactions, such as angioedema (swelling) and symptoms of shock.

Official Safety Restrictions

Specific restrictions define when the medicine should not be used. Citicoline is contraindicated in individuals with a known hypersensitivity to the drug's components. It is also restricted for use in patients with a history of vagal hypertonia (persistent overstimulation of the parasympathetic nervous system).

Separately, official documents advise caution or restriction regarding use during pregnancy and lactation due to the absence of sufficient regulatory data for these populations. Additionally, the medicine should not be administered at the same time as products containing meclofenoxate.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Citicoline is defined by its very low toxicity classification in humans, which dictates the required emergency response. Prescribing information consistently documents that the compound has a low toxicity profile and intoxication is unlikely to occur, even if therapeutic doses are accidentally exceeded.

Documented Overdose Profile

Feature Official Regulatory Documentation
Documented Presentations Citicoline is formally characterized by its very low toxicity profile, and regulatory documents note that no case of overdose has been reported in some jurisdictions. Severe clinical manifestations are not listed or anticipated.
Physiological Effects Regulatory data confirm that studies involving administration exceeding therapeutic doses did not result in significant changes or abnormalities in hematology, clinical biochemistry, or neurological tests, reflecting the benign profile.
Urgent Help Requirements Official labeling does not define specific symptoms or scenarios that require an immediate, mandatory call to emergency services, nor does it list specific population-based overdose risks.

Emergency Action

The mandated procedural action for accidental overdose is strictly limited to administering symptomatic therapy. This guidance confirms that no specific antidote is required or listed in the official prescribing information. The lack of documented severe outcomes means that regulators only specify supportive care, reflecting the compound's established safety profile.

Therapeutic Uses of Citicholine

What Citicoline Treats: Main Uses and Benefits

Citicoline is commonly applied across therapeutic domains where additional symptomatic support is needed. Its primary utility is centered on addressing symptoms that interfere with daily functioning associated with long-term neurological challenges. The support provided is relevant when supportive symptom management is appropriate, particularly in conditions where functional stability becomes affected.

Clinically, it is used in situations involving certain distressing symptoms for conditions such as cerebrovascular disorders, the sequelae of traumatic brain injury, and certain instances of age-related cognitive impairment and symptoms linked to organ-specific functional stress (referring to optic nerve issues).

Quick Fact: Supportive Role in Cognitive Function

Area of Use Primary Symptom Managed Patient Benefit
Neurorehabilitation Symptoms that interfere with daily functioning Assists with maintaining functional stability
Cognitive Support Memory, attention, and focus strain Helps improve day-to-day comfort
Ocular Health Symptoms linked to organ-specific functional stress Supports general well-being during symptomatic phases

Eligibility and Restrictions for Use

The official regulatory profile for Citicoline defines eligibility by explicit contraindications and conditional use requirements across certain populations. The medicine is absolutely contraindicated for patients with a known hypersensitivity to citicoline or any other component of the product. Use is also prohibited in patients who have hypertonia of the parasympathetic nervous system.

The primary established population for use is adults and the elderly, where no dose adjustment is typically required. However, use is restricted in several populations due to insufficient data or specific risk factors.

Use in children is not generally recommended due to limited clinical experience. Administration to pediatric patients is conditional, only permitted when the expected therapeutic benefit is determined to outweigh the potential risk. Similarly, use during pregnancy and breastfeeding is restricted, and allowed only if the official assessment finds that the benefit to the mother justifies the potential risk to the fetus or infant.

Specific caution is mandated for patients with persistent intracranial hemorrhage, as the administration of large doses or rapid infusion could potentially aggravate cerebral blood flow. Caution is also required for patients with a medical history of Parkinson's disease, trimethylaminuria, or depression.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documentation for Citicoline defines a concise interaction profile, focusing on specific drug–drug interactions rather than broad metabolic pathways. All information presented reflects formal interaction outcomes and restrictions specified in government prescribing information.


Formally Prohibited Combinations

Citicoline is subject to an absolute restriction regarding co-administration with certain substances. The co-administration of Citicoline with medicinal products containing Meclofenoxate (also known as Clophenoxate or Centrophenoxine) is strictly prohibited. This combination is formally classified as a contraindicated combination in the regulatory prescribing information.


Pharmacodynamic Interactions

A specific pharmacodynamic interaction is documented with Levodopa (L-dopa). Official labeling states that co-administration of Citicoline results in the potentiation of Levodopa’s effects. This indicates an additive or synergistic effect described within the official documents.


Undocumented Interaction Categories

Regulatory documents do not explicitly list information regarding several common interaction categories. No specific interaction mechanisms involving pharmacokinetic enzymes (such as the CYP450 system) or drug transport proteins have been documented. Furthermore, no formal interaction patterns are officially specified for co-use with food, alcohol, herbal products, or supplements, nor are there any mandatory timing or dose separation requirements.

Mechanism of Action

Citicholine is hydrolyzed into its components, cytidine and choline, upon ingestion. The choline moiety is utilized as an immediate precursor in the Kennedy pathway for the synthesis of phosphatidylcholine (PtdCho). This process enhances the availability and subsequent incorporation of PtdCho into neuronal cell membranes, thereby modulating membrane fluidity and receptor function.

Additionally, the increased free choline availability supports the synthesis of the neurotransmitter acetylcholine (ACh), leading to enhanced cholinergic signaling and modulation of synaptic plasticity via interaction with nicotinic and muscarinic receptors. Furthermore, Citicholine alters the activity of the enzyme phospholipase A2, which results in the reduction of free radical formation and the modulation of free fatty acid release, key intracellular consequences of ischemia. These actions collectively modify cellular processes involved in neurotransmission and membrane homeostasis.

Dosage and Administration Information

How to Use Citicoline: Administration Guidelines

This section outlines the administration and dosing instructions for Citicoline.


Administration and Dosage

Citicoline is available for use via multiple routes and dosage forms.

Route of Administration Typical Adult Daily Dosage Range
Oral (Tablets, Capsules, Solution) 500 mg to 2000 mg
Parenteral (IM or IV Injection) 500 mg to 1000 mg

Dosing Frequency: The standard regimen is typically a total daily dose administered once daily or as a divided dose (e.g., twice daily).


Key Procedural Instructions

The proper use protocol includes specific conditions related to administration and patient population:

  • Oral Administration: Citicoline can generally be taken without regard to meals.
  • Intravenous (IV) Administration: IV injection must be administered very slowly, typically over a period of 3 to 5 minutes, or via slow infusion.
  • Elderly Patients: General guidelines indicate no mandatory dose adjustment is required based solely on age.
  • Children: Specific lower doses may be prescribed; use should only be considered when the therapeutic benefit clearly outweighs the potential risks.

Note on Usage Protocol

These instructions define the standardized approach for using Citicoline, setting the forms, dosing schedule, and critical administration conditions. Do not deviate from the prescribed route or speed of administration.

Recent Clinical Evidence

Citicoline: Recent Clinical Evidence

Citicoline (CDP-choline) is an endogenous compound and an intermediate in the synthesis of phosphatidylcholine, a key component of neuronal cell membranes. Research has explored its use primarily in conditions involving cerebral injury or cognitive decline, such as stroke, traumatic brain injury (TBI), and vascular cognitive impairment.

Findings in Acute Ischemic Stroke

Clinical data on citicoline's effect following acute ischemic stroke has yielded inconsistent results. While some early trials and pooled analyses suggested a potential for improved neurological and functional outcomes in certain patient subgroups (often those with moderate-to-severe strokes, as defined by the NIHSS score), larger, more definitive randomized controlled trials have generally not demonstrated a significant benefit on global recovery measures at 90 days.

Findings in Cognitive Impairment

  • Vascular Cognitive Impairment (VCI): Studies, particularly long-term, randomized trials, have explored whether citicoline is associated with better cognitive status and quality of life in patients who have experienced a first ischemic stroke. Some results suggest an association with a slower rate of cognitive decline in domains such as attention, executive function, and temporal orientation over several months to two years.
  • Other Cognitive Deficits: Citicoline has also been studied in patients with mild cognitive impairment (MCI) and age-related memory decline. Some research indicates that supplementation may be associated with improvements in attention and memory function, especially in individuals with lower baseline cognitive performance.

Safety Profile

Overall, citicoline is widely considered to have a favorable safety profile and is generally well-tolerated across various neurological trials, including those lasting up to 12 months or longer. The most frequently reported adverse events are typically mild and transient, primarily involving gastrointestinal upset and headache.

Frequently Asked Questions (FAQ)

Common questions about Citicholine (FAQ)


Q: How does Citicholine work to support brain health?

Citicholine is a compound involved in the biosynthesis of phosphatidylcholine, a major component of cell membranes. Research suggests its administration may provide nutritional support by promoting the repair of damaged neuronal membranes. It is classified as a nootropic supplement intended to support healthy cognitive function.


Q: Is Citicholine safe to take with other supplements?

Individuals considering taking Citicholine alongside other supplements or medications should consult with a healthcare professional or pharmacist. This is important to review potential interactions, particularly with agents that affect dopamine or acetylcholine levels, to ensure safety and appropriateness.


Q: How long does it take for Citicholine to show an effect?

The time required to observe any effect from nutritional supplements like Citicholine can vary significantly among individuals. Clinical studies related to cognitive support have typically evaluated outcomes over periods ranging from several weeks to several months. Consistent use, as part of a regimen determined by a healthcare provider, is generally recommended.

How should Citicholine be stored and disposed of?

Storage and Disposal of Citicoline According to Regulatory Labeling

The storage and handling of Citicoline must strictly adhere to the conditions mandated by official regulatory labeling to ensure product quality and public safety.

Mandatory Storage Requirements

Temperature and Environment: Citicoline must be stored at temperatures not exceeding 30°C (86°F). The medicine must also be kept in a dry place and protected from light.

Child Safety: It is mandatory to keep this medicine out of the sight and reach of children.

Official Disposal Instructions

Prohibited Disposal: Unused or expired Citicoline must not be thrown away via wastewater or household waste.

Proper Procedure: Consult a pharmacist on how to dispose of medicines you no longer use. This disposal method is required to help protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Citicholine found in:

A-Z Index: